TMIGD2 and gastric cancer: Although there was no difference in 5‐year OS between high B7H5 expression and low expression in the nucleus among patients with GC (28.0% vs 21.6%, P = .254), survival analysis showed that a high cytoplasmic B7H5 expression predicted poorer survival than a low cytoplasmic B7H5 expression in patients with GC (19.6% vs 37.5%, P = .035), while GC patients with high CD28H had poorer survival (39.4% vs 6.9%, P = .002).